Asia Deal Watch: Bharat Expands Its Vaccine Holdings By Buying GSK’s Chiron Behring
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
You may also be interested in...
A month after Genfit’s Phase III failure, Inventiva hits multiple endpoints in a Phase IIb study of pan-PPAR agonist lanifibranor – likely drawing partnering or acquisition interest. Ascletis offers Phase II evidence for its NASH drug.
South Korean medical product manufacturer BioGenetics, which has recently diversified into the biopharma business and entered alliances for novel anticancer drugs, aims to further beef up its pharma activities through the acquisition of Kyung Nam Pharm, which will secure distribution networks at home and abroad.
Deals among domestic Chinese biotechs are growing fast, reflecting a need to huddle up amid tightening scrutiny over biotech deal-making and an unusually competitive immuno-oncology market.